Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of co-administration of Ad26.COV2.S with seasonal influenza vaccines in healthy adults
2021-003953-43Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ad26.COV2.S, influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated) and Efluelda in coronavirus disease 2019 (COVID-19) and influenza (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Hemagglutinin inhibition antibody geometric mean titers. Started Sep 2021; status: completed.
02
Drugs
Ad26.COV2.Sinfluenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated)Efluelda
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on 2021-003953-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003953-43.